Pediatric rheumatology

Screening for comorbid autoimmune disease should be considered in children with antinuclear antibody (ANA) positive juvenile idiopathic arthritis – results from the south-Swedish juvenile idiopathic arthritis cohort

Pediatr Rheumatol Online JPublished Population-based matched cohort study

Main finding · Autoimmune diseases in generalResult — go to the resultHazard ratio 4.11 95% CI 2.13–7.91

Authors' conclusion

Individuals with JIA have a significantly increased risk of being diagnosed with an autoimmune condition after receiving their JIA diagnosis compared to matched references. ANA positivity is associated with a further increased risk.

Study context

Population
Population-based juvenile idiopathic arthritis (JIA) cohort, southern Sweden, diagnosed 2000–2010, followed until 2019matched cohort
Participants
302 vs 1,510
Exposure
JIA cohort vs age- and sex matched reference population
  • JIAn = 302
  • Reference populationn = 1,510reference
Outcome
Comorbid autoimmune conditions diagnosed after JIA diagnosis
Methodological detailsage- and sex matched reference population, Cox proportional models, validated JIA diagnosis
  • Age- and sex matched reference population
  • Cox proportional models
  • Validated JIA diagnosis

Main finding

Autoimmune diseases in general · within the first 7 years of disease

Hazard ratio

4.11

95% CI 2.13–7.91

By group

JIA

7.7%

JIAvs Reference population
HR 4.11 (95% CI 2.13–7.91)

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeHR (95% CI)
Coeliac disease5.24 (1.76–15.65)
Hypothyroidism3.74 (1.14–12.30)

Comorbid autoimmune disease by ANA positivity, within JIA cohort

HR (95% CI)
ANA positiveSignificantly increased risk6.21 (1.64–23.55)

Original publication

Screening for comorbid autoimmune disease should be considered in children with ANA positive juvenile idiopathic arthritis – results from the south-Swedish juvenile idiopathic arthritis cohort. Pediatr Rheumatol Online J. Published 19 October 2024. doi:10.1186/s12969-024-01030-x

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.